John S Kent: Cholesterol matrix delivery system for sustained release of macromolecules. Syntex, Ellen J Buckles, Tom M Moran, Alan M Krubiner, June 5, 1984: US04452775 (221 worldwide citation)

Delivery systems for releasing macromolecular active agents to a body site at a controlled rate for a prolonged period of time, comprising a cholesteric matrix permeable to passage of the macromolecular active agent by diffusion, are disclosed. The cholesteric matrix comprises cholesterol powder and ...

Deborah A Eppstein, Brian B Schryver: Controlled release of macromolecular polypeptides. Syntex, Lester E Johnson, Tom M Moran, Alan M Krubiner, October 9, 1990: US04962091 (196 worldwide citation)

An active agent delivery system for the controlled administration of macromolecular polypeptides which comprises a micro-suspension of water-soluble components in a polylactide matrix.

Norman G Gaylord: Method for correcting visual defects, compositions and articles of manufacture useful therein. Syntex, Alan M Krubiner, Joseph I Hirsch, October 17, 1978: US04120570 (185 worldwide citation)

Visual defects of the human eye in the form of refractive errors such as myopia, hyperiopia, astigmatism, athakis and keratoconus are corrected by a therapeutic method which includes the step of fitting to the patient's eye a corrective contact lens fabricated from a copolymer of a polysiloxanylalky ...

Cheng Der Yu, Ursula Bruenner: Carbonate diester solutions of PGE-type compounds. Syntex, James M Kanagy, Alan M Krubiner, Tom M Moran, May 4, 1982: US04328245 (136 worldwide citation)

Stable compositions of PGE-type compounds are achieved by dissolving those compounds in carbonate diester solvents which may contain water up to the solubility limit of the carbonate diester.

Cheng Der Yu: Acetal stabilized prostaglandin compositions. Syntex, James M Kanagy, Alan M Krubiner, Tom M Moran, November 9, 1982: US04358603 (88 worldwide citation)

Degradation of prostaglandins in anhydrous or aqueous pharmaceutically acceptable, water-miscible alcohol solutions is prevented by adding a stabilizing amount of a pharmaceutically acceptable acetal.

Andreas Supersaxo, Jim H Kou: Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles. Syntex, William Schmonsees, Theodore J Leitereg, Alan M Krubiner, November 28, 1995: US05470582 (79 worldwide citation)

A controlled release pharmaceutical composition comprising a physiologically active agent dispersed in preformed porous polymeric microparticles is provided. The active agent concentration may be up to about 10% by weight to achieve controlled release. Each of the porous microparticles has a plurali ...

L David Waterbury: Use of pyrrolo pyrroles in treatment of ophthalmic diseases. Syntex, Hana Dolezalova, Tom M Moran, Alan M Krubiner, June 12, 1984: US04454151 (60 worldwide citation)

Certain known pyrroles have been found to be useful in the topical treatment of various ophthalmic diseases in mammals; especially those originating from or associated with inflammation such as, for example, cystoid macular edema, glaucoma, conjunctivitis, uveitis, diabetic retinopathy and eye surge ...

Julien P Verheyden, John C Martin: 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent. Syntex, Annette M Moore, Alan M Krubiner, October 19, 1982: US04355032 (59 worldwide citation)

The compound 9-(1,3-dihydroxy-2-propoxymethyl)guanine and the pharmaceutically acceptable salts thereof are useful as antiviral agents.

Keith A M Walker, John J Bruno, Gregory R Martinez: Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors. Syntex, Brian Lewis, Tom M Moran, Alan M Krubiner, December 20, 1988: US04792561 (58 worldwide citation)

The invention concerns a method of inhibiting both thromboxane synthetase and cyclic-AMP phosphodiesterase in a mammal having a disease characterized by elevated thromboxane levels or an imbalance of prostacyclin/thromboxane levels with a compound of the formula: ##STR1## or a pharmaceutically accep ...